Ipsen: approval of Cabometyx-Opdivo in advanced RCC
(CercleFinance.com) - Ipsen has announced that the European Commission has approved its Cabometyx (cabozantinib), in combination with Bristol Myers Squibb's Opdivo (nivolumab), for the first-line treatment of advanced renal cell carcinoma (RCC).
This decision will enable market access for Cabometyx, combined with Opdivo, for this indication in the 27 EU Member States, as well as in Norway and Iceland. This is the third indication for Cabometyx in RCC.
The phase III CheckMate 9ER study showed that the combination doubled the median progression-free survival and significantly improved overall survival and disease control rates with a lower discontinuation rate compared to sunitinib.
Copyright (c) 2021 CercleFinance.com. All rights reserved.
This decision will enable market access for Cabometyx, combined with Opdivo, for this indication in the 27 EU Member States, as well as in Norway and Iceland. This is the third indication for Cabometyx in RCC.
The phase III CheckMate 9ER study showed that the combination doubled the median progression-free survival and significantly improved overall survival and disease control rates with a lower discontinuation rate compared to sunitinib.
Copyright (c) 2021 CercleFinance.com. All rights reserved.